← Leaderboards
Johnson Ung
University Of Virginia
$221,286
Attributed
$221,286
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $99.2K · FY2022–25$100K$75K$50K$25K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$221,286 · 3
By mechanism
K00$99,216 · 1
F99$76,342 · 1
F31$45,728 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Thomas P Loughran$27,014,958
- Scott O Zeitlin$8,386,162
- Sasanka Ramanadham$7,414,754
- Decio Laks Eizirik$2,179,666
- Sarah C Wang$180,232
Others in their field
Other Rising Stars on “Sampling”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Sabrina Paganoni · Massachusetts General Hospital$20,824,388
- Suma Babu · Massachusetts General Hospital$20,824,388
Research focus
SamplingAffectOuter Mitochondrial MembraneResponseMalignant NeoplasmsSignal TransductionMcl1 GeneMyelogenousProtein FamilyResistanceBone Marrow FailureEquilibriumAcute Myelocytic LeukemiaApoptosisAcute Myeloid Leukemia CellApoptoticMemberCell LineGeneticInhibitorProteinsBcl2l1 GeneEnzymesLipids
Grant awards (5)
BH3 Profiling in AML to Measure Apoptotic Signaling Kinetics of Approved Drugs and Identify Integrated Stress Response Apoptotic Susceptibilities$99,216
K00 · FY2025 · CA · contact PI
Mechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia$38,061
F99 · FY2024 · CA · contact PI
Mechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia$38,281
F99 · FY2023 · CA · contact PI
Targeting Acid Ceramidase and Bcl-2 in Acute Myeloid Leukemia$10,113
F31 · FY2023 · CA · contact PI
Targeting Acid Ceramidase and Bcl-2 in Acute Myeloid Leukemia$35,615
F31 · FY2022 · CA · contact PI